Omalizumab or dupilumab suggested for adults with moderate-to-severe allergic asthma, history of exacerbations requiring oral corticosteroids<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
THURSDAY, Jan. 22, 2026 (HealthDay News) — In a clinical practice guideline issued by the American College of Chest Physicians and published online in CHEST<\/em>, recommendations are presented to optimize the use of biologic agents for severe asthma in adults.<\/p>\n Amber J. Oberle, M.D., from Duke University in Durham, North Carolina, and colleagues conducted a systematic review and meta-analysis and developed recommendations relating to the choice of biologic agent in severe asthma for adult patients.<\/p>\n The authors developed seven recommendations. Among these recommendations, they suggest using either omalizumab or dupilumab in adults with moderate-to-severe allergic asthma and a history of one or more exacerbations per year requiring oral corticosteroids; dupilumab is suggested over omalizumab for those with frequent exacerbations or any severe exacerbation requiring hospitalization and for patients with a greater impairment in lung function, while omalizumab is suggested over dupilumab for patients with more severe impairments in quality of life. Either anti-IL5\/5R\u03b1 therapy or dupilumab is suggested for adults with severe asthma who are steroid-dependent. Dupilumab is suggested over tezepelumab for adults with severe asthma who are steroid dependent. Either anti-IL5\/5R\u03b1 therapy or dupilumab is suggested for adults with moderate-to-severe asthma who have not demonstrated a clinical response to omalizumab after four to six months; dupilumab or tezepelumab are suggested for adults with severe asthma who have not demonstrated a clinical response to anti-IL5\/5R\u03b1 therapy after four to six months.<\/p>\n “In addition to following this guideline, decisions as to how to individualize biological therapy should occur under a shared decision-making process that carefully considers underlying asthma comorbidities, T2 biomarkers, injection frequency, mode of administration, and access to resources,” Oberle said in a statement.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n